Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies

NCT00697346 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00697346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00697346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 11, 2008
Completion date
October 19, 2016
Enrollment
58 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, b-cell chronic lymphocytic leukemia, b-cell follicular lymphoma, b-cell mantle cell lymphoma, b-cell marginal zone lymphoma, b-cell small lymphocytic lymphoma, diffuse large b-cell lymphoma, enteropathy associated t-cell lymphoma, multiple myeloma, nk lymphoma, noncutaneous peripheral t-cell lymphoma not otherwise specified, waldenstrom's macroglobulinemia